


PHARMACEUTICAL 2023



ELITE PHARMACEUTICALS INC NV Rank 66 of 446





PHARMACEUTICAL 2023



ELITE PHARMACEUTICALS INC NV Rank 66 of 446



The relative strengths and weaknesses of ELITE PHARMACEUTICALS INC NV are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELITE PHARMACEUTICALS INC NV compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 144% points. The greatest weakness of ELITE PHARMACEUTICALS INC NV is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 189% points above the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 18,861 |
| Cost of Goods Sold | 17,467 |
| Intangible Assets | 6,634 |
| Liabilities, Current | 6,694 |
| Liabilities, Non-Current | 3,233 |
| Other Assets | 3,700 |
| Other Compr. Net Income | 0 |
| Other Expenses | -527 |
| Other Liabilities | 0 |
| Other Net Income | 2,091 |
| Other Revenues | 32,262 |
| Property and Equipment | 5,953 |
| Research and Development | 4,051 |
| Selling, General and Administrative Expense | 4,464 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 35,149 |
| Liabilities | 9,927 |
| Expenses | 25,455 |
| Revenues | 32,262 |
| Stockholders Equity | 25,222 |
| Net Income | 8,898 |
| Comprehensive Net Income | 8,898 |
| Economic Capital Ratio | 232% |

